CAAS Capital Management’s Yarrow Bioscience YARW Stock Holding History

CAAS Capital Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-329	Closed	-$2.05M	–	618
2020 Q2	$2.05M	Buy	+329	New	+$2.23M	0.07%	207

Other funds holding YARW

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

CAAS Capital Management's YARW Position: Q3 2020 in Review

CAAS Capital Management sold out of Yarrow Bioscience (YARW) in Q3 2020, closing a stake of 329 shares — an estimated $2.05M sold.

CAAS Capital Management first reported a position in YARW in Q2 2020 and held it in 1 quarter. The position peaked at $2.05M in Q2 2020. 97 funds tracked by Wall St. Rank hold YARW as of Q3 2020.

CAAS Capital Management reported no remaining Yarrow Bioscience position as of Q3 2020 after selling out during the quarter.
CAAS Capital Management sold 329 Yarrow Bioscience shares in Q3 2020, an estimated $2.05M.
CAAS Capital Management first reported a position in Yarrow Bioscience in Q2 2020 and held it in 1 quarter.
CAAS Capital Management's Yarrow Bioscience position peaked at $2.05M in Q2 2020.
97 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.